This report describes the evolution of Cord Blood (CB) hematopoietic stem cell transplants (HSCTs) in Europe over time and its current status. There were 687 patients with a first CB HSCT and a total of 763 allogeneic CB HSCT but no autologous CB HSCT reported in the year 2008. The 687 first transplants correspond to 6% of the total 11,408 allogeneic HSCT. All CB HSCT were for haematological indications; there were no CB transplants reported amongst the 598 cellular transplants listed for non-hematopoietic use. Indications were different depending on donor type. Main indications for the 48 HLA identical family donors CB HSCT were non-malignant disorders (36; 75%) and acute leukaemia (8; 17%). Main indications for the 639 unrelated first CB HSCT were acute leukaemia (337;53%), non-malignant disorders (115;18%) and lymphoproliferative disorders (53; 8%). 159 teams out of the 368 teams performing allogeneic HSCT (43%) reported 1 to 37 CB HSCT (median 3). There were significant differences in use of CB in the participating European countries with a median CB transplant number of 6.5 (range 1-207), transplant rate (number of CB HSCT/10 million inhabitants) of 6.3 (range 0.1-234.6) and a proportion of CB amongst allogeneic HSCT from 0.7% to 18.2% (median 5.4%). These data document the established role of CB HSCT in Europe but point to significant differences in its use.
Gratwohl A, Baldomero H, Lanza F (2010). European survey on clinical use of cord blood for hematopoietic and non hematopoietic indications. BONE MARROW TRANSPLANTATION, 42, 265-275 [10.1016/j.transci.2010.03.008].
European survey on clinical use of cord blood for hematopoietic and non hematopoietic indications
Lanza FMembro del Collaboration Group
2010
Abstract
This report describes the evolution of Cord Blood (CB) hematopoietic stem cell transplants (HSCTs) in Europe over time and its current status. There were 687 patients with a first CB HSCT and a total of 763 allogeneic CB HSCT but no autologous CB HSCT reported in the year 2008. The 687 first transplants correspond to 6% of the total 11,408 allogeneic HSCT. All CB HSCT were for haematological indications; there were no CB transplants reported amongst the 598 cellular transplants listed for non-hematopoietic use. Indications were different depending on donor type. Main indications for the 48 HLA identical family donors CB HSCT were non-malignant disorders (36; 75%) and acute leukaemia (8; 17%). Main indications for the 639 unrelated first CB HSCT were acute leukaemia (337;53%), non-malignant disorders (115;18%) and lymphoproliferative disorders (53; 8%). 159 teams out of the 368 teams performing allogeneic HSCT (43%) reported 1 to 37 CB HSCT (median 3). There were significant differences in use of CB in the participating European countries with a median CB transplant number of 6.5 (range 1-207), transplant rate (number of CB HSCT/10 million inhabitants) of 6.3 (range 0.1-234.6) and a proportion of CB amongst allogeneic HSCT from 0.7% to 18.2% (median 5.4%). These data document the established role of CB HSCT in Europe but point to significant differences in its use.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.